The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol

• Status: Unknown status
• Trial end date: 2021-06-10
• Target enrollment: 0
• Participant gender: All

Summary

To observe the effect of thalidomide combined with megestrol acetate on lymphocyte, inflammatory factor regulation and nutritional status in patients with advanced malignant tumors.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shenzhen Fifth People's Hospital
• Treatments: Megestrol; Megestrol Acetate; Thalidomide

Criteria

Inclusion Criteria:

• Patients with advanced malignant tumor confirmed by histopathology or cytology (hepatocarcinoma can be clinical diagnosis)

• Must be able to swallow pills

• The age of the tester ≥ 18 years old

• Gender is not limited

• Kamofsky score > 20 points

• Estimated survival period ≥ 2 months

• Childbearing age Women need negative pregnancy test

• Patients voluntarily sign informed consent and receive follow-up

• The tester can cooperate to observe adverse events and efficacy

• All of the above conditions can be included

Exclusion Criteria:

• Active upper digestive tract ulcers, obvious vomiting, chronic diarrhea, intestinal obstruction, malabsorption, etc; other patients have been known to affect drug absorption, distribution, metabolism or clearance

• 2 or more important organ dysfunction

• Thrombosis Embolism history, except for thrombosis caused by PICC

• Patients suspected of having a history of allergy to thalidomide tablets

• Any significant clinical and laboratory abnormalities that researchers believe affect safety evaluators, such as: uncontrollable activity Microbial infection, grade II or above peripheral neuropathy (NCI CTC AE v4.0), congestive heart failure, myocardial infarction within 6 months, chronic kidney disease, thyroid dysfunction etc, and acceptance may bring significant metabolic or weight changes Patients with clinical disposition

• Patients with mental disorders, affecting the efficacy of the assessor

• During the trial period and within 3 months after the end of the trial, the subject and his partner are not willing to contraception

• Any of the above can not be enrolled.